Form panel to check pharma practices, SC directs govt.

1. At a Glance

• On 8 October 2026 the Supreme Court directed the Union government to set up an expert committee to look at how the rules on unethical pharmaceutical marketing can be made stronger. [1][2]
• The case is about whether the Uniform Code for Pharmaceutical Marketing Practices (UCPMP), 2024 should get statutory backing. Today the code is issued by the Department of Pharmaceuticals (DoP) as an executive code, not passed by Parliament as a law. [2][3]
• Why it matters for UPSC: it ties together several syllabus themes:
• the doctor–pharma nexus and Article 21 (right to health)
• drug prices and irrational prescribing
• self-regulation versus statutory regulation
• judicial directions to the executive

2. Why in the News

• 8 Oct 2026: The SC told the Union government to form an expert committee within two weeks. [1][2]
• The committee must consult stakeholders and submit recommendations within two months of its first meeting. [1]
• The committee will examine statutory regulations for pharma marketing, including gifts and other benefits given to doctors. [2]
• The Solicitor General proposed a three-member committee. It would decide whether a statutory framework is needed and, if so, what form it should take. [2]
• The case was heard on petitions from the Federation of Medical and Sales Representatives' Associations of India (FMRAI) and others. [1][2]

3. Background & Evolution

• UCPMP, 2015: the first DoP code for pharma marketing. It was voluntary and had no penalties. [4]
• Aug 2022: FMRAI told the SC that the makers of Dolo-650 had given doctors freebies worth about ₹1,000 crore to prescribe the drug. [5][6]
• Aug 2022: The SC asked the Centre to file its reply within 10 days. [7]
• Sept 2022: In separate litigation, pharma companies argued in the High Court that drug samples given to doctors are not "freebies". [8]
• Mar 2024: The DoP notified UCPMP, 2024, which replaced the 2015 code. [3][9]
• Mar 2024: FMRAI called UCPMP 2024 "an exercise in vain" because it has no legal enforceability. [10]
• Dec 2024: The DoP reprimanded AbbVie Healthcare for unethical marketing practices. This was an example of enforcement under the code. [11]
• Nov 2025: The SC observed that people should get a "proper remedy" against malpractices by pharma firms. [12]
• Oct 2026: The SC ordered the expert committee. [1][2]

4. Core Static Facts

5. Multi-Dimensional Analysis

Legal / Constitutional

• The central question is whether the voluntary or executive UCPMP should become an enforceable statute. [2][10]
• Right to health is read into Article 21. Marketing incentives can distort prescriptions, which affects patients' access to rational and affordable treatment. The SC's "proper remedy" remark reflects this concern. [12]
• This is an example of the court directing the executive to deliberate, through a committee with fixed deadlines, rather than writing the law itself. [1][2]

Ethical / Governance

• Conflict of interest: gifts and hospitality to doctors and their families weaken a doctor's independent clinical judgement. [3]
• Accountability gap: FMRAI argues that a code without penalties cannot stop malpractice. [10]
• Regulatory asymmetry: NMC ethics rules bind doctors, while the UCPMP binds companies. Neither side faces a common statutory penalty. (Note: this is background context and not confirmed in the retrieved sources.)

Economic

• Freebie-driven prescribing raises out-of-pocket expenditure. The alleged ₹1,000-crore Dolo-650 spend shows how large such marketing budgets can be. [5]
• The debate over whether samples count as "freebies" affects industry compliance costs and how such spending is treated for tax. [8]

Social

• Poorer patients are hit hardest by irrational or brand-driven prescriptions.
• Medical representatives, the petitioners here, say they face sales targets that push them into unethical practices. [10]

Administrative

• Under the code, complaints are handled through industry-association ethics committees with DoP oversight. The AbbVie reprimand shows the limited sanctions available. [11]
• The open question is which body would enforce a statutory regime: the DoP, the CDSCO (under the Health Ministry) or the NMC.

6. Recent Developments (last 12-18 months)

• Dec 2024: DoP reprimanded AbbVie Healthcare under the UCPMP. [11]
• Nov 2025: The SC said people must get a proper remedy against pharma malpractices. [12]
• 8 Oct 2026: The SC directed that an expert committee be formed within 2 weeks, with recommendations due within 2 months of its first meeting. The Solicitor General proposed a 3-member panel. [1][2]

7. Prelims Hooks

• UCPMP, 2024 was issued by the Department of Pharmaceuticals, not the Health Ministry or CDSCO. [3]
• The DoP sits under the Ministry of Chemicals & Fertilizers. [4]
• UCPMP 2024 replaced UCPMP 2015. [3][4]
• The UCPMP bars gifts and monetary benefits to HCPs and their family members. [3]
• The UCPMP restricts travel and hospitality to HCPs for conferences, subject to conditions. [3]
• The UCPMP has no statutory backing; the SC questioned whether its enforcement is adequate. [2]
• Petitioner in the SC case: Federation of Medical and Sales Representatives' Associations of India. [1]
• Allegation in the Dolo-650 case: ₹1,000 crore in freebies to doctors (2022). [5]
• SC order of 8 Oct 2026: committee to be formed within 2 weeks. [1][2]
• The committee's report is due 2 months after its first meeting, not 2 months after the order. [1]
• The Solicitor General proposed a three-member committee. [2]

8. Why the 2024 Code Cannot Really Punish Anyone

• Companies are judged by their own industry first
• A complaint under the UCPMP goes first to an ethics committee run by the industry association. It can then go up to an apex committee [2].

• So the first judge of a drug company is a body made up of drug companies. That is self-regulation (an industry policing itself).

• The code has no penal provision (no written punishment)

• The code does not say how a company that breaks the rules will be punished [2].

• So the strongest step seen so far is a reprimand, a formal warning, as in the AbbVie case [11]. A warning costs a company far less than a marketing budget that can run into crores [5].

• The main safeguard is a promise from the company head

• After the 2024 code, the government asked pharma company chiefs to sign an undertaking (a written promise) to follow ethical practices [14].

• The company signs its own promise and nobody checks it from outside. A signed promise only works if breaking it has a price.

• Audits were announced, but the SC still doubts they happen

• In March 2024 the DoP said it would form a panel of auditors for risk-based marketing audits of drug firms. Risk-based means checking the firms most likely to break the rules first [15].
• In September 2025 the SC asked whether the ethical norms were "actually" implemented at all [16]. Its Nov 2025 "proper remedy" remark followed [12].

9. Doctors Lose Their Licence, Companies Walk Free

• The rules bind only one side of the deal
• The ethics rules can be enforced against doctors, but not against the drug companies [2].

• So a doctor's licence can be cancelled for taking a benefit, while the company that offered it faces no legal penalty [2].

• Why this matters

• A gift needs a giver and a taker. Punishing only the taker leaves the giver free to try the next doctor.

• The petitioners argue that, without a law behind it, the code can even make doubtful promotion look legitimate. A company can say "we follow the code" while the code has no teeth [2].

• Who brought the case tells you something

• The petitioners are medical representatives, the sales staff who carry out these practices [1].
• They say sales targets push them into unethical marketing [10]. A law that penalises the company, not just the field worker or the doctor, puts the pressure where the targets are set.

10. The Case Against a New Law, and Where It Falls Short

• The strongest objection: some spending is legitimate
• Not every payment by a company is a bribe. Free drug samples, medical education and conference support can help doctors.

• Pharma companies have already argued in court that samples given to doctors are not "freebies" [8]. A blunt law could treat useful spending as a crime and invite endless legal fights over definitions.

• What this objection gets right

• A statute (a law passed by Parliament) needs exact definitions. A loose word like "freebie" will be challenged in court.

• The 2024 code already allows travel and support for conferences only under set conditions [3]. So the line between allowed and banned spending can be drawn. The law should copy that line, not erase it.

• Where the objection fails

• The voluntary approach has now been tried for about ten years: the 2015 code, then the 2024 code [4][3]. In that time came the ₹1,000-crore Dolo-650 allegation [5] and an SC that is still asking whether the rules are followed at all [16].
• The problem the case raises is not unclear definitions. It is that breaking even clear rules costs a company almost nothing [2][11].

11. Another Committee: What It Must Answer This Time

• This road has been taken before
• In September 2022, soon after the Dolo-650 allegation, the government formed a 5-member high-level committee to review pharma marketing practices [13].

• What came out was the 2024 code, which still has no legal force [2][10]. A new committee that produces only another code would repeat the same result.

• Why the SC chose a committee with deadlines

• The court cannot write a law itself. Making laws is Parliament's job.

• So it fixed timelines instead: the panel within 2 weeks, the report 2 months after its first meeting [1]. This keeps the matter moving without the court acting as the lawmaker.

• The three questions the panel cannot avoid

• Who enforces? The DoP issues the code [3], but drug regulation and doctors' conduct sit with other bodies. If no single body is named, nothing changes.
• What is the penalty for a company? The present gap is exactly this [2].
• Who sits in judgement? At present the first-level ethics committees belong to industry associations [2].

12. What Should Follow, and Who Should Do It

• Parliament should give the code legal force with penalties for companies
• At present only a doctor can lose a licence. The company that paid faces nothing [2].

• A statute should set a penalty for the company that is at least as serious as the doctor's.

• The DoP should take first-level complaints away from industry-only committees

• Today complaints start with the industry's own ethics committee [2].

• Independent members (doctors, patient groups, a government nominee) would stop companies from judging their own case.

• The DoP should carry out and publish the marketing audits it promised in 2024

• The auditor panel was announced in March 2024 [15], yet by September 2025 the SC still had to ask whether the norms were implemented [16].

• Published audit results would answer the court's question with evidence, not promises [14].

• The SC-ordered committee should clearly define allowed spending

• The "are samples freebies?" dispute [8] shows that unclear words lead to court cases.
• A clear list of what is allowed and what is banned protects genuine medical education and closes the loopholes.

13. Anchors for Answers

• Data: ₹1,000 crore: freebies allegedly given to doctors by the makers of Dolo-650 (alleged in the SC in 2022) [5]
• Report/Committee: 5-member high-level committee on pharma marketing practices formed by the government (Sept 2022) [13]; three-member expert committee proposed by the Solicitor General after the SC order of 8 Oct 2026 [2]
• Law/Case: Article 21 (right to health); FMRAI petition in the SC, with the court's remark that people must get a "proper remedy" (Nov 2025) [12] and its question on whether the norms are "actually" implemented (Sept 2025) [16]
• Scheme: DoP's risk-based marketing audit panel under UCPMP 2024 [15]; undertaking on ethical practices from pharma company chiefs [14]

14. Mains Relevance

• GS-II: Health (issues relating to the development and management of the social sector); government policies and interventions; role of the judiciary.
• GS-III: Industry (the pharma sector) and consumer protection.
• GS-IV: Conflict of interest, professional ethics, corporate governance.
• Question stems: 1. Self-regulation in the pharmaceutical sector has failed to curb unethical marketing. Critically examine the case for giving statutory backing to the UCPMP. (GS-II, 15 marks) 2. The doctor–pharma nexus is as much an ethical problem as a regulatory one. Discuss. (GS-IV) 3. Examine how judicial directions have shaped health regulation in India, with reference to recent cases. (GS-II)

15. Related Topics to Study Next

• Drugs and Cosmetics Act, 1940 / CDSCO: the main drug-regulation statute; shows how far drug regulation can reach marketing.
• NMC (Registered Medical Practitioner Professional Conduct) Regulations: the ethics rules on the doctors' side of the relationship.
• NPPA and DPCO, 2013: price control, which links marketing to drug affordability.
• Jan Aushadhi and generic prescription mandates: policy alternatives to brand-driven prescribing.
• Income-tax treatment of pharma freebies: freebies as a disallowed expense, which links to Section 37 jurisprudence.
• Consumer Protection Act, 2019 (misleading advertisements): a parallel route to accountability.
• Drugs, Medical Devices and Cosmetics Bill (draft): proposed new legislation that may absorb marketing rules.

16. NCERT Concepts to Revise

• Right to health (Polity): The case rests on the right to health under Article 21, as marketing incentives distort prescriptions.
• Right to life and personal liberty (Polity): Article 21 is the constitutional base from which the Supreme Court derives health and 'proper remedy' concerns.
• National Medical Commission (Polity): The NMC regulates doctors' conduct, the doctor-side counterpart to the company-side marketing code.
• Consumer protection (Economy): Unethical drug marketing exploits patients as consumers; consumer law offers a parallel route to accountability.
• Price control (Economy): Freebie-driven prescribing affects drug affordability, linking marketing rules to government price regulation of medicines.
• Judiciary (Polity): The Supreme Court is directing the government to form a committee, showing judicial intervention in policy.

17. Common Errors / Trap Areas

• Wrong ministry: the UCPMP comes from the DoP under the Ministry of Chemicals & Fertilizers, not MoHFW, CDSCO or NMC. [3][4]
• Legal status: the UCPMP 2024 is not a statute and does not come from an Act of Parliament. Making it statutory is exactly what the SC case is about. [2]
• Petitioner's name: it is a medical representatives' federation (FMRAI), not a doctors' or patients' body. Some reports write the acronym as FMSRAI. [1][2]
• Deadline wording: the 2 months run from the committee's first meeting, not from the date of the SC order. The committee itself must be formed within 2 weeks. [1]
• Dates: the 2015 code was voluntary and the 2024 code replaced it. Do not mix up which year's code is under challenge. [3][4]